ライフサイエンスコーパス: first-line therapy

1 evel of efficacy required for their use as a first line therapy.

2 avitreal antibiotic delivery was a universal first-line therapy.

3 patients achieved a complete response after first-line therapy.

4 acy rate (<80%) and should not be adopted as first-line therapy.

5 of HIV-infected patients receiving DTG-based first-line therapy.

6 ertuzumab, which is now included as standard first-line therapy.

7 tients did not have access to this option as first-line therapy.

8 ggests caution in prescribing rituximab as a first-line therapy.

9 th a higher rate of early death when used as first-line therapy.

10 use of rituximab both as second-line and as first-line therapy.

11 uring or within 6 months of the last dose of first-line therapy.

12 r vemurafenib (960 mg twice daily) orally as first-line therapy.

13 b monotherapy (960 mg twice-daily) orally as first-line therapy.

14 e evaluated lenalidomide plus rituximab as a first-line therapy.

15 atment and after 3, 6, and 9 days of empiric first-line therapy.

16 ed, but available data support penicillin as first-line therapy.

17 high-quality evidence supports its use as a first-line therapy.

18 n was time-to-treatment failure (TTF) of the first-line therapy.

19 able relapses identified by slow response to first-line therapy.

20 ts a stepwise approach with acetaminophen as first-line therapy.

21 s in CLL patients receiving current-standard first-line therapy.

22 therapy are challenging its current role as first-line therapy.

23 ed into question the use of glycopeptides as first-line therapy.

24 f intravitreal antibiotics was the universal first-line therapy.

25 acy and safety of pazopanib and sunitinib as first-line therapy.

26 han half of patients are cured with standard first-line therapy.

27 th high genetic barrier to resistance as the first-line therapy.

28 glabrata and echinocandins are often used as first-line therapy.

29 ed to the proteasome inhibitor bortezomib, a first-line therapy.

30 further erodes the position of vancomycin as first-line therapy.

31 evidence of better IDI response when used as first-line therapy.

32 t candidates received standard site-specific first-line therapy.

33 Outcome was not affected by the choice of first-line therapy.

34 allo-SCT in all myeloma patients as part of first-line therapy.

35 re and 3 and/or 6 months after initiation of first-line therapy.

36 ul in approximately 60% of cases that failed first-line therapy.

37 ance, which makes alpha-agonists the logical first-line therapy.

38 genetic barrier to resistance are considered first-line therapy.

39 ercent of patients received bevacizumab with first-line therapy.

40 EGFR TKI or chemotherapy is the appropriate first-line therapy.

41 therapy, but no data exist about its use as first-line therapy.

42 ternative therapy (switch maintenance) after first-line therapy.

43 h advanced NSCLC after progression following first-line therapy.

44 disease progressing more than 6 months after first-line therapy.

45 causes more then 50% mortality rate despite first-line therapy.

46 ieved at least stable disease after standard first-line therapy.

47 ses a mortality rate of at least 50% despite first-line therapy.

48 al expertise, either option is acceptable as first-line therapy.

49 ocumented clinical progression subsequent to first-line therapy.

50 all-cell lung cancer (SCLC) after failure of first-line therapy.

51 19-2020), and 54% of patients were receiving first-line therapy.

52 age, who were considered for curative-intent first-line therapy.

53 rant, as compared with anastrozole alone, as first-line therapy.

54 ring, and restricted use of beta-blockers as first-line therapy.

55 ed and fit patients in need of highly active first-line therapy.

56 he use of raltegravir 1200 mg once daily for first-line therapy.

57 astric cancer and progressed during or after first-line therapy.

58 onary tuberculosis received standard 6-month first-line therapy.

59 inimal residual disease level achieved after first-line therapy.

60 -proxetil) are not as effective as empirical first-line therapies.

61 lter P. falciparum susceptibility to current first-line therapies.

62 ny people reporting ongoing symptoms despite first-line therapies.

63 ies were included in analysis of efficacy of first-line therapies.

64 for inclusion in the analysis of efficacy of first-line therapies.

65 nefits and harms compared with each other as first-line therapy?

66 49 (42%) of 116 patients failed first-line therapy, 2-year survival was 88% (95% CI 81-9

67 of 25 of 28 patients with progression during first-line therapy, 31 of 32 with progression during rei

68 Among 82 patients evaluable for response to first-line therapy, 31 patients received neoadjuvant che

69 plantation (allo-SCT) for myeloma as part of first-line therapy, a donor versus no-donor analysis was

70 optimal selection of therapeutic strategy or first-line therapy adjustment.

71 diagnosed ovarian cancer patients respond to first-line therapy, almost all relapse and five-year sur

72 udy aimed to: (1) examine the utilization of first-line therapy among HR+/HER2+/MBC patients and (2)

73 for patients with DLE that is refractory to first-line therapies and who risk late-stage disease wit

74 Intensive first-line therapy and "lymphoid-type" chemotherapy regi

75 e a strong recommendation for hydroxyurea as first-line therapy and a weak recommendation for chronic

76 alone and in combination with rituximab as a first-line therapy and as a treatment of patients with r

77 c drug therapy is generally recommended as a first-line therapy and drug selection is on the basis of

78 s are lacking benzodiazepines are considered first-line therapy and N-Methyl-d-aspartate receptor ant

79 ntify which patients should receive standard first-line therapy and which should receive a protease-i

80 immunotherapy 2-5 months after completion of first-line therapy and who were assessed as having a hig

81 s alone, radioiodine is increasingly used as first line therapy, and is the preferred choice for rela

82 8% of those on treatment were on recommended first-line therapies, and 30% were on lamivudine monothe

83 by geographic region, time to progression on first-line therapy, and disease measurability, was used.

84 g to the presence of metastases, duration of first-line therapy, and Karnofsky performance status.

85 stant disease progressing within 6 months of first-line therapy, and randomised trials might be appro

86 es; (2) second-line LA-ART for those failing first-line therapy; and (3) first-line LA-ART for ART-na

87 Treatment after failure of those first-line therapies are disappointing overall, with man

88 nsensus sequences from patients treated with first-line therapies between 1989 and 2013 to confirm th

89 Oral iron is usually recommended as first-line therapy, but the most recent intravenous iron

90 Adopting either as a first-line therapy carries major cost and resource impli

91 As a first-line therapy, combined Endo and Epi VT ablation in

92 rtion of complete hematologic response after first-line therapy compared to patients with a dFLC leve

93 clear-cell carcinoma who progressed despite first-line therapy containing sunitinib, bevacizumab plu

94 PI-based first-line therapy could be reconsidered when antiretrov

95 inuous positive airway pressure is generally first-line therapy despite low adherence, because it rel

96 e addition of evofosfamide to doxorubicin as first-line therapy did not improve overall survival comp

97 Statins are first-line therapy drugs for cholesterol lowering.

98 delines recommend a maximum of six cycles of first-line therapy, even in responding patients, recent

99 sease should be offered endocrine therapy as first-line therapy, except in cases of visceral crisis o

100 t option in NMO patients who do not tolerate first-line therapy, experience ongoing relapses or in si

101 rove the infection treatment efficacy.If the first-line therapy fails a second-line treatment using t

102 promote non-pharmacological interventions as first line therapy for depression and anxiety in people

103 agent, MitoQ, alone and in combination with first line therapy for DKD.

104 on-selective beta-adrenergic blocker that is first line therapy for infantile hemangioma.

105 st that surgical resection should remain the first line therapy for patients with HCC and compensated

106 -Retroviral Therapy (ART) is the recommended first line therapy for patients with HIV.

107 tic allergy labels result in displacement of first-line therapies for antibiotic prophylaxis and trea

108 l therapy that demonstrated superiority to 2 first-line therapies for AR.

109 Glucocorticoids (GCs) are used as first-line therapies for generalized suppression of infl

110 First-line therapies for HIT are argatroban or lepirudin

111 rspective of co-targeting NO metabolism with first-line therapies for improved outcome.

112 ment (TME) hampers the long-term efficacy of first-line therapies for lung cancer.

113 Vancomycin and metronidazole are first-line therapies for most patients, although treatme

114 l (3 g in a single dose) are all appropriate first-line therapies for uncomplicated cystitis.

115 Cisplatin is a cytotoxic drug used as a first-line therapy for a wide variety of cancers.

116 make this a reasonable option to consider as first-line therapy for achalasia.

117 and development, prevention of osteoporosis, first-line therapy for active disease, and maintenance o

118 The first-line therapy for acute TTP is based on daily thera

119 ifestyle modification, metformin remains the first-line therapy for adolescents with type 2 diabetes,

120 oad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell ca

121 stage IIIB-IV KRAS-mutant NSCLC; had failed first-line therapy for advanced NSCLC; had WHO performan

122 fit of adding evofosfamide to doxorubicin as first-line therapy for advanced soft-tissue sarcomas.

123 l-asparaginase (ASNase) is a first-line therapy for ALL that breaks down asparagine a

124 Insulin is first-line therapy for all women with preexisting diabet

125 l experience with proteasome inhibition as a first-line therapy for AMR is presented.

126 n thiazides and thiazide-like diuretics as a first-line therapy for any outcome.

127 Lithium is a first-line therapy for bipolar affective disorder.

128 Lithium is the first-line therapy for bipolar disorder.

129 Statins are first-line therapy for cardiovascular disease prevention

130 ion with topical corticosteroid therapy as a first-line therapy for chronic sinusitis.

131 nd without CIP (n=6), prior to initiation of first-line therapy for CIP (high dose corticosteroids.

132 emoimmunotherapy (CIT) has been the standard first-line therapy for CLL.

133 Forty-two percent had isolates resistant to first-line therapy for community-acquired pneumonia.

134 Present first-line therapy for diffuse large B-cell lymphoma, a

135 To assess a short course of cyclosporine as first-line therapy for DIHS.

136 While benzodiazepines are a first-line therapy for Dravet syndrome, they are limited

137 Guidelines recommend statins as first-line therapy for dyslipidemia.

138 Standard first-line therapy for EGFR-mutant advanced non-small-ce

139 nase inhibitor, is emerging as the preferred first-line therapy for EGFR-mutant lung cancer, yet resi

140 al-acting corticosteroids are recommended as first-line therapy for eosinophilic esophagitis (EoE).

141 omycin-based regimens are commonly used as a first-line therapy for Helicobacter pylori-positive pati

142 cizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor rec

143 Polyclonal anti-D is a first-line therapy for immune thrombocytopenia (ITP).

144 Zanamivir should be considered as first-line therapy for influenza in patients with lympho

145 TIP demonstrated efficacy as first-line therapy for intermediate- and poor-risk GCTs

146 TEVAR has become first-line therapy for many aortic pathologies including

147 ncreased PFS when combined with docetaxel as first-line therapy for MBC compared with docetaxel plus

148 in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRY

149 in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRY

150 tinib to improve the survival has become the first-line therapy for metastatic RCC patients.

151 Oral and rectal 5-ASA are recommended first-line therapy for mild to moderate UC, with cortico

152 shock wave lithotripsy (SWL), a noninvasive first-line therapy for millions of nephrolithiasis patie

153 Although corticosteroids remain the first-line therapy for most forms of HESs, the availabil

154 Nafcillin and cefazolin are considered first-line therapy for most infections with methicillin-

155 costeroids (CSs) and cyclosporine A (CsA) as first-line therapy for newly diagnosed cGVHD after allo-

156 us chemotherapy versus chemotherapy alone as first-line therapy for non-squamous non-small-cell lung

157 h lifestyle interventions are considered the first-line therapy for nonalcoholic fatty liver disease

158 of combination nivolumab plus ipilimumab as first-line therapy for NSCLC.

159 with macrolides, including azithromycin, as first-line therapy for patients hospitalized with pneumo

160 e per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast can

161 2018, osimertinib has been widely adopted as first-line therapy for patients with advanced EGFR-mutan

162 y and safety of nilotinib versus imatinib as first-line therapy for patients with advanced GISTs.

163 e only Food and Drug Administration-approved first-line therapy for patients with advanced hepatocell

164 agulation) should be routinely considered as first-line therapy for patients with extensive acute ili

165 The first-line therapy for patients with keratitis is differ

166 dermal growth factor receptor (EGFR) are the first-line therapy for patients with metastatic colorect

167 of pembrolizumab plus pemetrexed-platinum as first-line therapy for patients with metastatic non-squa

168 r superior to paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-n

169 using doxycycline appears to be a reasonable first-line therapy for patients with OAML.

170 with bleomycin in general or specifically as first-line therapy for patients with treatment naive, ad

171 When choosing between anti-VEGF and PRP as first-line therapy for PDR, treatment decisions should b

172 Benzodiazepines are considered first-line therapy for pediatric status epilepticus.

173 to be approved for clinical use, and remains first-line therapy for Philadelphia chromosome (Ph+)-pos

174 trimethoprim-sulfamethoxazole is considered first-line therapy for Pneumocystis pneumonia prevention

175 deprivation is currently a standard-of-care, first-line therapy for prostate cancer in the United Sta

176 -positive patients who received tamoxifen as first-line therapy for recurrent or metastatic disease,

177 IFN-beta has been used as a first-line therapy for relapsing-remitting multiple scle

178 atinum-based drug cisplatin is a widely used first-line therapy for several cancers.

179 Parenteral artesunate is recommended as first-line therapy for severe malaria.

180 angiotensin-converting enzyme inhibitors as first-line therapy for SRC, and give recommendations for

181 tion as an alternative to stent retriever as first-line therapy for stroke thrombectomy.

182 Anakinra as first-line therapy for systemic JIA was associated with

183 ib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP

184 elective beta-blocker propranolol has become first-line therapy for the treatment of complicated infa

185 Although opioids remain a first-line therapy for the treatment of severe chronic p

186 h surgical controls and should be considered first-line therapy for this disease.

187 Metformin is the first-line therapy for treating type 2 diabetes and a pr

188 the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer.

189 Metformin is first-line therapy for type 2 diabetes mellitus, althoug

190 The evidence supports metformin as first-line therapy for type 2 diabetes, given its relati

191 Metformin, a first-line therapy for type 2 diabetes, is the only drug

192 mbolization (TACE) is currently considered a first-line therapy for unresectable HCC.

193 Topical corticosteroids are the current first-line therapy for vulvar lichen sclerosus (VLS).

194 (SABA) delivered by metered-dose inhaler as first-line therapy for younger and older children (hospi

195 b in the treatment of CLL, particularly as a first-line therapy, gave indications that idelalisib may

196 Participants aged 18 years or older for whom first-line therapy had failed, with HIV RNA concentratio

197 ne therapy in HIV-infected patients for whom first-line therapy had failed.

198 oaches with the use of more potent agents as first-line therapy has been proposed, but they are still

199 IV drug resistance among individuals in whom first-line therapy has failed and clinical and resistanc

200 ns, and outline options for patients in whom first-line therapy has failed.

201 Balloon angioplasty, the first-line therapy, has a tendency to lead to subsequent

202 Gains from first-line therapies have been modest but consistent; ho

203 efficacy of cryoballoon ablation as initial first-line therapy have not been established.

204 ell lung cancer (NSCLC) who progress through first-line therapy have poor progression-free survival (

205 tis (SAR) and to compare its efficacy with 2 first-line therapies (ie, intranasal azelastine and intr

206 tes that corticosteroids can be an effective first line therapy in treating orbital inflammation in s

207 reatment or catheter ablation are considered first-line therapies in most patients with PVCs associat

208 Finally, the safety and efficacy of standard first-line therapies in paediatric multiple sclerosis po

209 Glucocorticoids are considered first-line therapy in a variety of eosinophilic disorder

210 We conducted a phase 2 single-group trial of first-line therapy in adults with newly diagnosed Ph-pos

211 when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, prima

212 irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-t

213 port the use of noninvasive ventilation as a first-line therapy in appropriately selected critically

214 D-1 inhibitors supports using this option as first-line therapy in circumstances where rapid response

215 Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndro

216 EGFR-TKI osimertinib has been approved as a first-line therapy in NSCLC, representing the most succe

217 The administration of nab-PC as first-line therapy in patients with advanced NSCLC was e

218 aphy (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgk

219 irolimus to letrozole did not improve PFS as first-line therapy in patients with AI-naive advanced br

220 em cell transplantation (autoSCT) as part of first-line therapy in patients with chronic lymphocytic

221 Although cisplatin (CDDP) has been used as a first-line therapy in patients with EAC, resistance rema

222 inase inhibitors (TKIs) are being offered as first-line therapy in patients with EGFR activating muta

223 S and ORR over standard-of-care sunitinib as first-line therapy in patients with intermediate- or poo

224 ated cabozantinib compared with sunitinib as first-line therapy in patients with mRCC.

225 vestigate the safety and efficacy of SIRT as first-line therapy in patients with uveal melanoma metas

226 Thrombolytic therapy should be considered first-line therapy in pregnant patients with prosthetic

227 in the management of urethral strictures as first-line therapy in selected patients.

228 orting the use of vasopressin analogs as the first-line therapy in the ICU setting with knowledge of

229 Crizotinib, a first-line therapy in the treatment of advanced non-smal

230 Although FOLFIRI was an acceptable first-line therapy in the treatment of AGC with a better

231 isceral leishmaniasis (VL), is currently the first-line therapy in the VL elimination program of the

232 mab plus chemotherapy versus chemotherapy as first-line therapy in Western (n = 923) and Chinese (n =

233 nosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%)

234 se these dietary treatments, perhaps even as first-line therapy, including infantile spasms, myocloni

235 Time to relapse after first-line therapy is a predictor of response to seconda

236 eoside analog gemcitabine frequently used in first-line therapy is an urgent issue in pancreatic canc

237 rst line therapy, widespread use of PI-based first-line therapy is not warranted at this time, due to

238 Resistance of HIV to first-line therapy is predictable at 12 months when eval

239 For treatment, the recommended first-line therapy is surgical removal, followed by marg

240 d patients at high risk for poor outcomes to first-line therapy (m7-Follicular Lymphoma International

241 cifically focusing on a strategy of multiple first-line therapies (MFT), and comparing it with strate

242 ic drugs have failed; however, its role as a first-line therapy needs further investigation.

243 Dantrolene is the first line therapy of malignant hyperthermia.

244 ollow-up studies, POEM may become one of the first-line therapies of achalasia in the next future.

245 linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC.

246 s focused on 806 patients receiving adjuvant first-line therapy of carboplatin and paclitaxel with cu

247 men represents a highly active treatment for first-line therapy of follicular non-Hodgkin's lymphoma.

248 g, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 y

249 r to standard ATRA and chemotherapy (CHT) in first-line therapy of low- or intermediate-risk acute pr

250 s benchmark end points for the CP regimen in first-line therapy of metastatic melanoma.

251 ) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repea

252 First-line therapy of severe aplastic anemia (SAA) with

253 at high doses, beta-adrenergic blockers, the first-line therapy, often are ineffective; the same is t

254 in combination with rituximab, are preferred first-line therapy options for symptomatic patients with

255 er, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine

256 with nonsteroidal anti-inflammatory drugs as first-line therapy, or tramadol or duloxetine as second-

257 adverse prognostic factor for survival after first-line therapy (P < .0001), independently of the int

258 For first-line therapy, patients in the EDP-mitotane group h

259 After 16 weeks of first-line therapy, patients with stable or responding t

260 emotherapy include the degree of response to first-line therapy, performance status, the likelihood o

261 alcium channel blocker ingestion (1D); 2) as first-line therapies (prioritized based on desired effec

262 Using bevacizumab in first-line therapy provided an additional 0.10 QALYs (0.

263 alysis found that etanercept-methotrexate as first-line therapy provided marginally more QALYs but ac

264 Despite improvements in first-line therapies, published results on the treatment

265 Patients (N = 86; 69 as first-line therapy) received cisplatin (n = 43) or carbo

266 ter arterial chemoembolization (TACE) is the first-line therapy recommended for patients with interme

267 mptoms for >=12 months despite being offered first-line therapies), recruited by letter and opportuni

268 echanism of proton pump inhibitors (PPIs) or first-line therapy remain unclear.

269 l is prolonging time to relapse by improving first-line therapy response.

270 VEGF-inhibiting agents should be confined to first-line therapy, second-line therapy or both.

271 ent medical need in patients failing current first-line therapies, such as with erythropoiesis-stimul

272 logue with a high barrier to resistance as a first-line therapy, such as entecavir or tenofovir, prov

273 ho progressed within 9 months after start of first-line therapy, then in all patients with adenocarci

274 Given the high frequency of failure of first-line therapies, there is an urgent need for second

275 utcome of patients treated with dasatinib as first-line therapy to identify patients who are more lik

276 CLRT-SLT may be offered as first-line therapy to patients with HCC and well-compens

277 pembrolizumab monotherapy can be extended as first-line therapy to patients with locally advanced or

278 rugs (NSAIDs) with or without menthol gel as first-line therapy to reduce or relieve symptoms, includ

279 cant improvements in patient outcomes for 26 first line therapy trials).

280 azole in Iran is low and this drug should be first line therapy, unless drug susceptibility testing s

281 were refractory or resistant (< 3 months) to first-line therapy warrants further development.

282 he ORR in 43 patients who never responded to first-line therapy was 16.3% (95% CI, 6.8% to 30.7%).

283 First-line therapy was four or more cycles of platinum d

284 s with aggressive non-Hodgkin lymphoma whose first-line therapy was guided by PET/CT had significantl

285 Moreover, lack of response to first-line therapy was the most dominant prognostic fact

286 tance implications of PI- versus NNRTI-based first line therapy, widespread use of PI-based first-lin

287 Catheter ablation is increasingly used as a first-line therapy with a high acute success rate, but r

288 ents with NSCLC who are being considered for first-line therapy with an EGFR TKI (patients who have n

289 nts with disease progression during or after first-line therapy with bevacizumab, oxaliplatin, and a

290 1 were analyzed in the CLL8 study evaluating first-line therapy with fludarabine and cyclophosphamide

291 ound has received additional FDA approval as first-line therapy with improvement in progression-free

292 In this study, first-line therapy with pembrolizumab in patients with a

293 ee survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and doc

294 Following first-line therapy with sorafenib or lenvatinib, second-

295 advanced hepatocellular carcinoma following first-line therapy with sorafenib.

296 ion who had locally defined viral failure on first-line therapy with tenofovir plus a cytosine analog

297 addition of either pertuzumab or placebo to first-line therapy with trastuzumab and docetaxel for pa

298 y cholangitis have an inadequate response to first-line therapy with ursodeoxycholic acid.

299 tane than with streptozocin plus mitotane as first-line therapy, with similar rates of toxic events,

300 ab (RTX) to high-dose dexamethasone (DEX) as first-line therapy yields higher sustained response rate